Search Results

There are 4257 results for: content related to: Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

  1. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Article first published online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Article first published online : 19 JUN 2012, DOI: 10.1002/mds.25051

  3. Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

    The Journal of Clinical Pharmacology

    Volume 50, Issue 12, December 2010, Pages: 1420–1428, Tamar Goren, Liat Adar, Nissim Sasson and Yoni M. Weiss

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010369674

  4. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition

    Journal of Neuroscience Research

    Volume 79, Issue 1-2, 1 - 15 January 2005, Pages: 172–179, Moussa B.H. Youdim, Orit Bar Am, Merav Yogev-Falach, Orly Weinreb, Wakako Maruyama, Makato Naoi and Tamar Amit

    Article first published online : 30 NOV 2004, DOI: 10.1002/jnr.20350

  5. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

    The Journal of Clinical Pharmacology

    Volume 52, Issue 5, May 2012, Pages: 620–628, Dr Jack J. Chen and Dr Jayne R. Wilkinson

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011406279

  6. Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl-2 Family Members with PKC Pathway

    Annals of the New York Academy of Sciences

    Volume 1053, Issue 1, August 2005, Pages: 348–355, ORLY WEINREB, TAMAR AMIT, ORIT BAR-AM, ORLY CHILLAG-TALMOR and MOUSSA B. H. YOUDIM

    Article first published online : 28 JUN 2008, DOI: 10.1111/j.1749-6632.2005.tb00043.x

  7. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease

    European Journal of Neurology

    Volume 19, Issue 2, February 2012, Pages: 258–264, E. Tolosa and M. B. Stern

    Article first published online : 5 AUG 2011, DOI: 10.1111/j.1468-1331.2011.03484.x

  8. You have free access to this content
    Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

    Journal of Neurochemistry

    Volume 105, Issue 5, June 2008, Pages: 1970–1978, Wen Zhu, Wenjie Xie, Tianhong Pan, Joseph Jankovic, Jun Li, Moussa B. H. Youdim and Weidong Le

    Article first published online : 8 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05330.x

  9. Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 10, October 2004, Pages: 1295–1305, Dr. John J. Thébault, Dr. Michel Guillaume and Dr. Ruth Levy

    Article first published online : 16 JAN 2012, DOI: 10.1592/phco.24.14.1295.43156

  10. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

    International Journal of Clinical Practice

    Volume 60, Issue 2, February 2006, Pages: 215–221, F. Stocchi

    Article first published online : 1 FEB 2006, DOI: 10.1111/j.1742-1241.2006.00806.x

  11. You have free access to this content
    The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

    Journal of Neurochemistry

    Volume 112, Issue 5, March 2010, Pages: 1131–1137, Orit Bar-Am, Orly Weinreb, Tamar Amit and Moussa B. H. Youdim

    Article first published online : 10 DEC 2009, DOI: 10.1111/j.1471-4159.2009.06542.x

  12. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  13. A Validated Normal Phase LC Method for Enantiomeric Separation of Rasagiline Mesylate and Its (S)-Enantiomer on Cellulose Derivative-Based Chiral Stationary Phase

    Chirality

    Volume 25, Issue 6, June 2013, Pages: 324–327, P. Sunil Reddy, K. Sudhakar Babu and Navneet Kumar

    Article first published online : 9 MAY 2013, DOI: 10.1002/chir.22150

  14. You have free access to this content
    Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

    Journal of Neurochemistry

    Volume 89, Issue 5, June 2004, Pages: 1119–1125, Orit Bar-Am, Merav Yogev-Falach, Tamar Amit, Yotam Sagi and Moussa B. H. Youdim

    Article first published online : 23 APR 2004, DOI: 10.1111/j.1471-4159.2004.02425.x

  15. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

    Movement Disorders

    Volume 19, Issue 8, August 2004, Pages: 916–923, Matthew B. Stern, Kenneth L. Marek, Joseph Friedman, Robert A. Hauser, Peter A. LeWitt, Daniel Tarsy and C. Warren Olanow

    Article first published online : 27 APR 2004, DOI: 10.1002/mds.20145

  16. Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

    Annals of the New York Academy of Sciences

    Volume 1122, Issue 1, December 2007, Pages: 155–168, ORLY WEINREB, TAMAR AMIT, ORIT BAR-AM and MOUSSA B.H. YOUDIM

    Article first published online : 10 DEC 2007, DOI: 10.1196/annals.1403.011

  17. Liquid chromatographic resolution of racemic rasagiline and its analogues on a chiral stationary phase based on (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid

    Journal of Separation Science

    Volume 36, Issue 23, December 2013, Pages: 3682–3687, Kyung Mi Tak, Eun Ju Park and Myung Ho Hyun

    Article first published online : 9 OCT 2013, DOI: 10.1002/jssc.201300819

  18. You have free access to this content
    Neuroprotection by Rasagiline: A New Therapeutic Approach to Parkinson's Disease?

    CNS Drug Reviews

    Volume 11, Issue 2, March 2005, Pages: 183–194, Fabio Blandini

    Article first published online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2005.tb00269.x

  19. The Anti-Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo

    Annals of the New York Academy of Sciences

    Volume 939, Issue 1, June 2001, Pages: 450–458, MOUSSA B.H. YOUDIM, A. WADIA, W. TATTON and MARTA WEINSTOCK

    Article first published online : 25 JAN 2006, DOI: 10.1111/j.1749-6632.2001.tb03656.x

  20. You have free access to this content
    Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

    British Journal of Pharmacology

    Volume 149, Issue 6, November 2006, Pages: 647–656, J P M Finberg, A Gross, O Bar-Am, R Friedman, Y Loboda and M B H Youdim

    Article first published online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706908